Literature DB >> 33400686

NOGOB receptor-mediated RAS signaling pathway is a target for suppressing proliferating hemangioma.

Wenquan Hu1,2,3, Zhong Liu2,3, Valerie Salato3, Paula E North3, Joyce Bischoff4, Suresh N Kumar3, Zhi Fang1,2,3, Sujith Rajan1, M Mahmood Hussain1, Qing R Miao1,2,3.   

Abstract

Infantile hemangioma is a vascular tumor characterized by the rapid growth of disorganized blood vessels followed by slow spontaneous involution. The underlying molecular mechanisms that regulate hemangioma proliferation and involution still are not well elucidated. Our previous studies reported that NOGOB receptor (NGBR), a transmembrane protein, is required for the translocation of prenylated RAS from the cytosol to the plasma membrane and promotes RAS activation. Here, we show that NGBR was highly expressed in the proliferating phase of infantile hemangioma, but its expression decreased in the involuting phase, suggesting that NGBR may have been involved in regulating the growth of proliferating hemangioma. Moreover, we demonstrate that NGBR knockdown in hemangioma stem cells (HemSCs) attenuated growth factor-stimulated RAS activation and diminished the migration and proliferation of HemSCs, which is consistent with the effects of RAS knockdown in HemSCs. In vivo differentiation assay further shows that NGBR knockdown inhibited blood vessel formation and adipocyte differentiation of HemSCs in immunodeficient mice. Our data suggest that NGBR served as a RAS modulator in controlling the growth and differentiation of HemSCs.

Entities:  

Keywords:  Angiogenesis; Cell cycle; Endothelial cells; Signal transduction; Vascular Biology

Mesh:

Substances:

Year:  2021        PMID: 33400686      PMCID: PMC7934876          DOI: 10.1172/jci.insight.142299

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  68 in total

Review 1.  Vascular Anomalies: From a Clinicohistologic to a Genetic Framework.

Authors:  Arin K Greene; Jeremy A Goss
Journal:  Plast Reconstr Surg       Date:  2018-05       Impact factor: 4.730

2.  Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells.

Authors:  Shoshana Greenberger; Elisa Boscolo; Irit Adini; John B Mulliken; Joyce Bischoff
Journal:  N Engl J Med       Date:  2010-03-18       Impact factor: 91.245

Review 3.  Infantile hemangioma.

Authors:  Kristen E Holland; Beth A Drolet
Journal:  Pediatr Clin North Am       Date:  2010-08-21       Impact factor: 3.278

4.  PDGFR-β (+) perivascular cells from infantile hemangioma display the features of mesenchymal stem cells and show stronger adipogenic potential in vitro and in vivo.

Authors:  Si-Ming Yuan; Yao Guo; Xiao-Jun Zhou; Wei-Min Shen; Hai-Ni Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

Authors:  M Agulnik; J L Yarber; S H Okuno; M von Mehren; B D Jovanovic; B E Brockstein; A M Evens; R S Benjamin
Journal:  Ann Oncol       Date:  2012-08-21       Impact factor: 32.976

6.  Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab.

Authors:  Michael R Jeng; Beng Fuh; Julie Blatt; Anita Gupta; Arnold C Merrow; Adrienne Hammill; Denise Adams
Journal:  Pediatr Blood Cancer       Date:  2014-04-17       Impact factor: 3.167

7.  Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice.

Authors:  Zia A Khan; Elisa Boscolo; Arnaud Picard; Sarah Psutka; Juan M Melero-Martin; Tatianna C Bartch; John B Mulliken; Joyce Bischoff
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 8.  Nogo and axon regeneration.

Authors:  Martin E Schwab
Journal:  Curr Opin Neurobiol       Date:  2004-02       Impact factor: 6.627

Review 9.  Vasculogenesis in infantile hemangioma.

Authors:  Elisa Boscolo; Joyce Bischoff
Journal:  Angiogenesis       Date:  2009-05-10       Impact factor: 9.596

10.  The Nogo-B receptor promotes Ras plasma membrane localization and activation.

Authors:  B Zhao; W Hu; S Kumar; P Gonyo; U Rana; Z Liu; B Wang; W Q Duong; Z Yang; C L Williams; Q R Miao
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

View more
  2 in total

Review 1.  Infantile hepatic hemangiomas: looking backwards and forwards.

Authors:  Xue Gong; Yanan Li; Kaiying Yang; Siyuan Chen; Yi Ji
Journal:  Precis Clin Med       Date:  2022-02-11

2.  Activatable "Matryoshka" nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer.

Authors:  Xinzhi Xu; Chunxiang Jin; Kai Zhang; Yang Cao; Junjun Liu; Yue Zhang; Haitao Ran; Ying Jin
Journal:  Mater Today Bio       Date:  2022-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.